Clinical Utility of the Harmony™ Prenatal Test in General Screening Population Highlighted During Fetal Medicine Foundation Course

Clinical Utility of the Harmony™ Prenatal Test in General Screening Population Highlighted During Fetal Medicine Foundation Course PR Newswire SAN JOSE, California, Dec. 3, 2012 SAN JOSE, California, Dec. 3, 2012 /PRNewswire/ -- Ariosa Diagnostics today announced that the Harmony™ Prenatal Test was featured during a presentation at the Fetal Medicine Foundation's "Advances in Fetal Medicine" course on Dec. 1, 2012 in London. Professor Kypros Nicolaides, M.D., director of the Fetal Medicine Centre (http://www.fetalmedicine.com/fmc/) and the Harris Birthright Research Centre for Fetal Medicine (http://www.harrisbirthright.org/), highlighted the center's clinical experience with the Harmony test as well as how to implement non-invasive prenatal testing (NIPT) with cell-free DNA (cfDNA) analysis in routine clinical practice for a general screening population. The center is currently offering the Harmony test to all pregnant women with a singleton pregnancy at 10 weeks of gestational age or later. More than 700 physicians and international experts from 70 countries in fetal medicine attended the course. http://www.fetalmedicine.com/fmc/ "Cell-free DNA testing, such as that with the Harmony test, represents a brilliant new development and must be offered as a routine test," Nicolaides said.